Calavo Growers (CVGW) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
14 Jan, 2026Executive summary
Net income from continuing operations grew 192% year-over-year to $20.0 million for fiscal 2025, with adjusted net income up 42% and adjusted EBITDA up 12% to $40.8 million.
Announced a strategic merger agreement with Mission Produce, expected to close by August 2026, creating a vertically integrated platform and targeting $25 million in cost synergies.
Management highlighted resilience amid challenges including facility shutdowns, FDA import holds, and a concluded FCPA investigation.
Financial highlights
Fiscal 2025 net sales decreased 2% year-over-year to $648.4 million; Q4 net sales fell 27% to $124.7 million.
Gross profit for fiscal 2025 was $63.7 million (10% margin), down from $67.8 million; Q4 gross profit was $11.6 million (9% margin).
SG&A expenses declined 16% to $42.1 million for the year.
Adjusted net income for fiscal 2025 was $28.9 million ($1.62 per diluted share), up 42% year-over-year.
Adjusted EBITDA for fiscal 2025 was $40.8 million, up 12% year-over-year.
Ended Q4 with $61.2 million in cash and $97.1 million in available liquidity; total debt was $4.1 million.
Outlook and guidance
Expects softer Q1 2026 results year-over-year due to continued strong avocado supply and pricing pressure.
Fresh segment: higher avocado volumes but lower prices and per unit profit; Prepared segment: volume-driven sales growth and higher gross profit.
Lower adjusted EBITDA anticipated in Q1 2026, mainly from Fresh segment pricing dynamics.
Latest events from Calavo Growers
- Shareholders to vote on a merger offering Calavo holders cash and Mission Produce stock at a premium.CVGW
Proxy filing20 Mar 2026 - Net sales fell 21%, but Prepared segment grew 20% and merger progress continued.CVGW
Q1 202612 Mar 2026 - Deal creates a top produce platform with $25M in synergies, closing by August 2026.CVGW
M&A announcement15 Jan 2026 - Annual meeting covers director elections, auditor ratification, compensation, and equity plan extension.CVGW
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and equity plan changes up for vote at annual meeting.CVGW
Proxy Filing1 Dec 2025 - Annual meeting set for April 23, 2025, with key proposals and voting details in proxy materials.CVGW
Proxy Filing1 Dec 2025 - Prepared segment growth and legal resolutions drove improved adjusted results despite FDA-related costs.CVGW
Q3 20259 Sep 2025 - Net sales up 12%, Fresh Cut sold, debt retired, and dividend doubled on strong avocado margins.CVGW
Q3 202413 Jun 2025 - Q2 net sales up 16.5% with margin gains; Fresh Cut sale and FCPA probe remain key themes.CVGW
Q2 202413 Jun 2025